A Complete Guide to Oncology and Cancer Care

What Is Oncology?

Cancer accounts for approximately 20 million new cases and 10 million deaths annually worldwide; it is the second leading cause of death globally and the first in high-income countries, according to GLOBOCAN 2022. Oncology is the branch of medicine dedicated to the prevention, diagnosis, and treatment of cancer. Cancer is not a single disease but rather a collection of more than 200 distinct conditions, all characterized by the uncontrolled growth and spread of abnormal cells. When the body's normal regulatory mechanisms for cell growth, division, and death break down, cells can proliferate without restraint, forming tumors that may invade surrounding tissues and spread (metastasize) to distant organs.

Cancer remains one of the leading causes of death worldwide, with approximately 20 million new cases and nearly 10 million deaths each year globally. However, advances in early detection, surgical techniques, targeted therapies, and immunotherapy have dramatically improved survival rates for many cancer types over the past several decades. Understanding the fundamentals of cancer care, including how cancer is assessed, staged, and treated, helps patients and their families navigate what is often a complex and overwhelming journey.

How Is Cancer Patient Performance Status Assessed?

ECOG performance status independently predicts chemotherapy toxicity and overall survival across all tumor types; patients with ECOG 3–4 have 3–5 times higher treatment-related mortality than those with ECOG 0. One of the most important assessments in oncology is the patient's performance status, which measures how well a person can carry out everyday activities and tolerate treatment. The ECOG Performance Status Calculator is the most widely used system for this purpose, employed by oncologists around the world to guide treatment decisions, determine eligibility for clinical trials, and estimate prognosis.

The ECOG scale ranges from 0 to 5. A score of 0 means the patient is fully active, able to carry out all pre-disease activities without restriction. A score of 1 indicates that the patient is restricted in physically strenuous activity but is ambulatory and able to carry out light or sedentary work. A score of 2 means the patient is ambulatory and capable of all self-care but unable to carry out any work activities, and is up and about more than 50 percent of waking hours. A score of 3 indicates the patient is capable of only limited self-care and is confined to a bed or chair more than 50 percent of waking hours. A score of 4 means the patient is completely disabled, cannot carry out any self-care, and is totally confined to a bed or chair. A score of 5 indicates death.

The ECOG score has profound implications for treatment planning. Patients with a performance status of 0 or 1 generally tolerate aggressive treatment well and have the best prognosis. Those with a score of 2 may benefit from treatment but with greater caution regarding toxicity. Patients with scores of 3 or 4 are generally not candidates for aggressive chemotherapy, as the risks of treatment toxicity typically outweigh potential benefits. Instead, these patients are more appropriately managed with supportive and palliative care focused on symptom control and quality of life. The ECOG score is also a key eligibility criterion for most clinical trials, ensuring that study results reflect outcomes in patients well enough to tolerate experimental treatments.

How Is Cancer Staged?

TNM staging is used to classify over 90% of solid tumors worldwide; 5-year survival rates vary dramatically by stage—from above 90% for stage I breast and colorectal cancers to below 15% for stage IV disease. Cancer staging describes the extent of cancer in the body and is essential for determining prognosis and selecting appropriate treatment. The TNM system, maintained by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC), is the most widely used staging framework worldwide.

The T component describes the size and extent of the primary tumor, ranging from T0 (no evidence of primary tumor) through T1 to T4 (increasing size and local invasion). Tis denotes carcinoma in situ, a very early cancer that has not yet invaded beyond the layer of cells where it originated. The N component describes the extent of regional lymph node involvement, from N0 (no regional lymph node metastasis) through N1 to N3 (increasing number and extent of affected nodes). The M component indicates the presence or absence of distant metastasis: M0 means no distant spread, while M1 means the cancer has spread to distant organs.

These three components are combined to assign an overall stage, typically expressed as Stage 0 (carcinoma in situ) through Stage IV (distant metastatic disease). Higher stages generally indicate more advanced disease with a less favorable prognosis, though the specific implications vary significantly by cancer type. For example, Stage III melanoma has a different prognosis and treatment approach than Stage III colon cancer.

What Are the Most Common Cancers and How Are They Screened?

The five most common cancers worldwide—lung, breast, colorectal, prostate, and stomach—together account for approximately 9.7 million deaths per year; lung cancer alone causes 1.8 million deaths annually (GLOBOCAN 2022). The most common cancers worldwide include breast cancer, lung cancer, colorectal cancer, prostate cancer, and skin cancer (both melanoma and non-melanoma types). Each has distinct risk factors, screening recommendations, and treatment approaches.

Breast cancer is the most commonly diagnosed cancer in women. Screening with mammography is recommended starting at age 40 to 50, depending on the guideline, with earlier and more intensive screening for women at high risk due to family history, genetic mutations (BRCA1/BRCA2), or prior chest radiation. Early-stage breast cancer is highly curable, with five-year survival rates exceeding 90 percent for localized disease.

Lung cancer is the leading cause of cancer death worldwide. The primary risk factor is tobacco smoking, which accounts for approximately 85 percent of cases. Low-dose CT screening is recommended for adults aged 50 to 80 with a significant smoking history (at least 20 pack-years). Early detection through screening can reduce lung cancer mortality by up to 20 percent.

Colorectal cancer screening, as discussed in the gastroenterology context, is recommended beginning at age 45 for average-risk adults. Prostate cancer screening with PSA testing involves shared decision-making between patient and provider, typically beginning at age 50 for average-risk men or age 40 to 45 for those at higher risk.

Skin cancer prevention focuses on sun protection (sunscreen, protective clothing, avoidance of tanning beds), and regular skin examinations can detect melanoma at an early, curable stage.

How Is Surgery Used to Treat Cancer?

Surgical resection is curative in approximately 80–90% of early-stage solid tumors; globally, 313 million major surgical procedures are performed annually, yet an estimated 143 million additional procedures are needed in underserved regions. Surgery is the oldest and, for many solid tumors, the most effective cancer treatment. The goal of curative surgery is to remove the entire tumor along with a margin of normal surrounding tissue to ensure no cancer cells remain. Modern surgical approaches have evolved significantly, with minimally invasive techniques including laparoscopic and robotic-assisted surgery offering smaller incisions, less pain, shorter hospital stays, and faster recovery for many cancer types.

Sentinel lymph node biopsy, a technique in which the first lymph node(s) likely to receive drainage from a tumor are identified and examined, has reduced the need for extensive lymph node dissections and their associated complications (such as lymphedema). For some cancers, surgery may be combined with preoperative (neoadjuvant) or postoperative (adjuvant) chemotherapy, radiation, or other systemic therapies to improve outcomes.

Not all cancers require or benefit from surgery. Some, like certain blood cancers (leukemias and lymphomas), are primarily treated with systemic therapies. Others may be too advanced at diagnosis for surgical cure, in which case surgery may still play a role in palliation (symptom relief).

How Does Chemotherapy Work?

Chemotherapy is used in the treatment of approximately 50% of all cancer patients; combination regimens have increased 5-year survival rates by 20–30% in leukemia, lymphoma, and testicular cancer compared to surgery alone. Chemotherapy refers to the use of cytotoxic drugs that kill rapidly dividing cells. These medications are administered intravenously or orally and circulate throughout the body, making them effective against cancer cells that have spread beyond the primary tumor site. Chemotherapy may be used as the primary treatment (for cancers such as leukemias and lymphomas), as adjuvant therapy (after surgery to eliminate residual microscopic disease), as neoadjuvant therapy (before surgery to shrink tumors), or as palliative therapy (to control symptoms and prolong life in advanced disease).

Because chemotherapy drugs target rapidly dividing cells, they also affect normal rapidly dividing tissues, leading to common side effects including nausea and vomiting, hair loss, mouth sores, fatigue, and increased susceptibility to infections due to reduced white blood cell counts. Significant advances in supportive care, particularly anti-nausea medications and growth factors that stimulate white blood cell production, have substantially improved the tolerability of chemotherapy regimens.

How Does Radiation Therapy Work?

Radiation therapy uses high-energy beams (most commonly X-rays or protons) to damage the DNA of cancer cells, preventing them from dividing and growing. It is used in approximately half of all cancer patients at some point during their treatment, either as definitive therapy (with curative intent), adjuvant therapy (after surgery), or palliative therapy (for symptom relief, such as pain from bone metastases).

Modern radiation therapy techniques, including intensity-modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), and proton therapy, allow precise targeting of tumors while minimizing exposure to surrounding normal tissues. Treatment is typically delivered in daily fractions over several weeks, though hypofractionated schedules (fewer treatments with higher doses per session) are increasingly used for select indications. Common side effects depend on the area being treated and may include skin irritation, fatigue, and localized symptoms specific to the treatment site.

How Do Immunotherapy and Targeted Therapy Work?

Immune checkpoint inhibitors have transformed outcomes in melanoma, lung cancer, and bladder cancer, with 5-year survival rates doubling in metastatic melanoma from approximately 10% before 2011 to over 25% by 2020. Immunotherapy has revolutionized cancer treatment over the past decade. Rather than directly attacking cancer cells, immunotherapy harnesses the patient's own immune system to recognize and destroy them. The most transformative class of immunotherapy drugs is immune checkpoint inhibitors, which block proteins (such as PD-1, PD-L1, and CTLA-4) that cancer cells use to evade immune detection. These drugs have produced durable responses in melanoma, lung cancer, kidney cancer, bladder cancer, and many other tumor types.

Other immunotherapy approaches include CAR-T cell therapy (in which a patient's own T cells are genetically engineered to target cancer cells), cancer vaccines, and bispecific antibodies. While immunotherapy has produced remarkable responses in some patients, it does not work for everyone, and it can cause immune-related side effects (when the activated immune system attacks normal tissues) that require careful monitoring and management.

Targeted therapy uses drugs designed to attack specific molecular abnormalities in cancer cells. Examples include HER2-targeted drugs for HER2-positive breast cancer, EGFR inhibitors for certain lung cancers, and BRAF inhibitors for BRAF-mutated melanoma. Because these drugs target specific molecular pathways, they tend to have different (and often more manageable) side effect profiles than traditional chemotherapy.

What Is Supportive and Palliative Care in Oncology?

Palliative care involvement from the time of advanced cancer diagnosis improves quality of life, reduces hospitalizations by approximately 30%, and—in randomized trials—extends median survival by 2.7 months compared to standard oncology care alone (NEJM Temel 2010). Supportive care encompasses all measures taken to prevent, manage, and alleviate the symptoms and side effects of cancer and its treatment. This includes pain management, nutritional support, psychological and emotional counseling, management of treatment side effects (nausea, fatigue, neuropathy), and treatment of complications such as infections.

Palliative care is a specialized form of supportive care focused on improving quality of life for patients with serious illness. Importantly, palliative care is not synonymous with end-of-life care; it can and should be provided alongside curative treatment from the time of diagnosis. Research has consistently shown that early integration of palliative care improves symptom burden, quality of life, patient satisfaction, and, in some studies, even overall survival. Palliative care teams typically include physicians, nurses, social workers, chaplains, and other specialists working together to address the physical, emotional, social, and spiritual needs of patients and their families.

What Is the Role of Clinical Trials in Cancer Treatment?

Only approximately 5% of adult cancer patients enroll in clinical trials; trials demonstrating superiority of new agents require median enrolment of 400–800 patients and take 5–10 years from inception to regulatory approval. Clinical trials are research studies that test new treatments, diagnostic tools, or prevention strategies in human volunteers. They are the primary mechanism by which new cancer therapies are developed and approved. Trials proceed through phases: Phase I studies assess safety and dosing in a small number of patients; Phase II studies evaluate efficacy and further assess safety; and Phase III studies compare the new treatment to the current standard of care in large, randomized groups of patients.

Participation in clinical trials gives patients access to promising new treatments that are not yet widely available. All clinical trials are closely monitored by institutional review boards and data safety monitoring committees to protect participants. Contrary to common misconception, patients in clinical trials receive at least the current standard of care; they are never given a placebo in place of proven treatment if an effective standard therapy exists. The ECOG performance status score, described earlier, is one of the most common eligibility criteria for oncology clinical trials.

What Does Cancer Survivorship Care Involve?

As of 2022, approximately 18.1 million cancer survivors live in the United States, a number projected to reach 26 million by 2040; survivorship care plans reduce recurrence detection delays and improve quality of life in this growing population. Cancer survivorship begins at the moment of diagnosis and extends through the balance of life. As treatment outcomes have improved, the population of cancer survivors has grown substantially, numbering over 18 million in the United States alone. Survivorship care addresses the long-term and late effects of cancer treatment, which may include fatigue, cognitive changes ("chemo brain"), neuropathy, cardiac toxicity, secondary cancers, infertility, and psychological challenges including anxiety, depression, and fear of recurrence.

Follow-up care after cancer treatment typically involves regular clinical visits, imaging studies, and blood tests to monitor for recurrence, manage ongoing treatment-related effects, and screen for new cancers. Survivorship care plans, which summarize the patient's diagnosis, treatment history, expected side effects, and recommended surveillance schedule, help coordinate care between oncologists and primary care providers. Healthy lifestyle practices, including regular physical activity, a balanced diet, maintaining a healthy weight, limiting alcohol, and avoiding tobacco, are increasingly recognized as important components of survivorship that can reduce the risk of recurrence and improve overall health outcomes.